Literature DB >> 7577448

Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine.

D H Horber1, P von Ballmoos, H Schott, R A Schwendener.   

Abstract

The clonogenic growth inhibition, the cell cycle dependence of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) cytotoxicity and the capability to induce apoptosis in ara-C-sensitive and -resistant HL-60 cells were investigated and compared with arabinofuranosylcytosine (ara-C). In the clonogenic assay with sensitive HL-60 cells, ara-C was slightly more effective than a liposomal preparation of NHAC, whereas in the resistant cells, NHAC revealed its potency to overcome ara-C resistance, resulting in a 23-fold lower 50% inhibitory concentration compared with ara-C. Cell cycle dependent cytotoxicity and induction of apoptosis were studied by flow cytometry, using the bromodeoxyuridine-propidium iodide and terminal transferase method respectively. In contrast to ara-C, NHAC exerted no phase-specific toxicity at low concentrations (< 40 microM). At higher concentrations the S-phase-specific toxicity increased, probably resulting from ara-C formed from NHAC. NHAC induced apoptosis at higher drug concentrations than ara-C, however apoptosis appeared not to be limited to the S-phase cells. Apoptosis occurred in both cell lines within 2-4 h after drug exposure. These results give further evidence that NHAC exerts its cytotoxicity by different mechanisms of action than ara-C and might therefore be active in ara-C-resistant tumours.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577448      PMCID: PMC2033964          DOI: 10.1038/bjc.1995.466

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Apoptosis. The role of the endonuclease.

Authors:  M J Arends; R G Morris; A H Wyllie
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

2.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.

Authors:  S H Kaufmann
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

3.  Evaluation of four methods of DNA distribution data analysis based on bromodeoxyuridine/DNA bivariate data.

Authors:  F Lacombe; F Belloc; P Bernard; M R Boisseau
Journal:  Cytometry       Date:  1988-05

4.  The locus of action of 1-beta-d-arabinofuranosylcytosine in the cell cycle.

Authors:  M Karon; S Shirakawa
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

5.  A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine.

Authors:  R L Momparler
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

6.  Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.

Authors:  K Bhalla; R Nayak; S Grant
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

Review 7.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

8.  Cell kinetic studies of the cytostatic and cytocidal effect of 1-beta-D-arabinofuranosylcytosine on the L1210 ascites tumor.

Authors:  R Fietkau; H Friede; B Maurer-Schultze
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

9.  Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosyl-cytosine, and etoposide.

Authors:  M Cavazzana; F Calvo; P Facchin; P Barreau; B Geny; L Dal Cortivo; C Dresch
Journal:  Exp Hematol       Date:  1988-11       Impact factor: 3.084

10.  Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.

Authors:  D H Horber; C Ottiger; H Schott; R A Schwendener
Journal:  J Pharm Pharmacol       Date:  1995-04       Impact factor: 3.765

View more
  3 in total

1.  In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.

Authors:  R A Schwendener; K Friedl; H Depenbrock; H Schott; A R Hanauske
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

2.  Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.

Authors:  R A Schwendener; H Schott
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.

Authors:  S K Koller-Lucae; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.